Alnylam Pharmaceuticals (ALNY) Financials

$285.56 -4.54 (-1.56%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$285.55 -0.01 (0.00%)

As of 05/28/2025 04:24 PM Eastern

Annual Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-278	-440	-1,131	-853	-858	-886	-761	-491	-410	-290
Consolidated Net Income / (Loss)	-278	-440	-1,131	-853	-858	-886	-761	-491	-410	-290
Net Income / (Loss) Continuing Operations	-278	-440	-1,131	-853	-858	-886	-761	-491	-410	-290
Total Pre-Tax Income	-377	-434	-1,127	-852	-856	-885	-761	-491	-410	-290
Total Operating Income	-177	-282	-785	-709	-828	-939	-815	-500	-425	-296
Total Gross Profit	1,925	1,518	869	704	415	195	73	90	47	41
Total Revenue	2,248	1,828	1,037	844	493	220	75	90	47	41
Operating Revenue	2,248	1,828	1,037	844	493	220	75	90	47	41
Total Cost of Revenue	323	310	169	140	78	25	1.80	0.00	0.00	0.00
Operating Cost of Revenue	323	310	169	140	78	25	1.80	0.00	-	-
Total Operating Expenses	2,102	1,800	1,654	1,413	1,243	1,134	888	590	472	337
Selling, General & Admin Expense	976	796	771	621	588	479	382	199	89	61
Research & Development Expense	1,126	1,004	883	792	655	655	505	391	382	276
Total Other Income / (Expense), net	-200	-151	-342	-143	-27	54	54	9.21	14	5.94
Interest Expense	142	121	233	143	84	0.00	0.00	-	-	-
Interest & Investment Income	122	96	25	1.58	-	33	29	12	8.31	5.86
Other Income / (Expense), net	-181	-126	-134	-2.05	57	21	25	-3.02	6.17	0.08
Income Tax Expense	-99	6.73	4.16	0.68	2.68	0.86	0.82	0.00	0.00	-
Basic Earnings per Share	($2.18)	($3.52)	($9.30)	($7.20)	($7.46)	($8.11)	($7.57)	($5.42)	($4.79)	($3.45)
Weighted Average Basic Shares Outstanding	127.65M	124.91M	121.69M	118.45M	114.99M	109.26M	100.59M	90.55M	85.60M	83.99M
Diluted Earnings per Share	($2.18)	($3.52)	($9.30)	($7.20)	($7.46)	($8.11)	($7.57)	($5.42)	($4.79)	($3.45)
Weighted Average Diluted Shares Outstanding	127.65M	124.91M	121.69M	118.45M	114.99M	109.26M	100.59M	90.55M	85.60M	83.99M
Weighted Average Basic & Diluted Shares Outstanding	129.46M	125.95M	124.13M	120.21M	114.99M	109.26M	100.59M	90.55M	85.60M	83.99M

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-57	-84	-112	-17	-66	-138	148	-276	-174	-207	-406
Consolidated Net Income / (Loss)	-57	-84	-112	-17	-66	-138	148	-276	-174	-207	-406
Net Income / (Loss) Continuing Operations	-57	-84	-112	-17	-66	-138	148	-276	-174	-207	-406
Total Pre-Tax Income	-42	-194	-109	-11	-64	-138	151	-274	-172	-207	-406
Total Operating Income	18	-105	-77	49	-43	-116	214	-230	-150	-189	-258
Total Gross Profit	523	490	415	591	428	354	666	233	264	284	223
Total Revenue	594	593	501	660	494	440	751	319	319	335	264
Operating Revenue	594	593	501	660	494	440	751	319	319	335	264
Total Cost of Revenue	71	103	86	69	66	86	84	85	55	51	41
Operating Cost of Revenue	71	103	86	69	66	86	84	85	55	51	41
Total Operating Expenses	505	596	492	543	472	470	452	463	414	472	481
Selling, General & Admin Expense	240	295	221	248	211	198	199	215	184	210	236
Research & Development Expense	265	300	271	294	261	272	253	249	231	262	245
Total Other Income / (Expense), net	-60	-89	-32	-60	-20	-21	-63	-44	-23	-18	-148
Interest Expense	39	39	34	33	35	31	31	30	29	30	118
Interest & Investment Income	29	31	32	29	30	30	25	21	19	14	7.82
Other Income / (Expense), net	-50	-81	-30	-56	-15	-20	-58	-35	-12	-2.57	-38
Income Tax Expense	16	-110	2.91	5.72	2.35	0.18	2.99	1.82	1.74	0.47	-0.02
Basic Earnings per Share	($0.44)	($0.66)	($0.87)	($0.13)	($0.52)	($1.09)	$1.18	($2.21)	($1.40)	($1.69)	($3.32)
Weighted Average Basic Shares Outstanding	129.68M	127.65M	128.59M	126.73M	126.14M	124.91M	125.22M	124.66M	124.11M	121.69M	122.17M
Diluted Earnings per Share	($0.44)	($0.66)	($0.87)	($0.13)	($0.52)	($1.06)	$1.15	($2.21)	($1.40)	($1.69)	($3.32)
Weighted Average Diluted Shares Outstanding	129.68M	127.65M	128.59M	126.73M	126.14M	124.91M	131.34M	124.66M	124.11M	121.69M	122.17M
Weighted Average Basic & Diluted Shares Outstanding	130.39M	129.46M	128.98M	128.38M	126.49M	125.95M	125.49M	125.00M	124.53M	124.13M	123.03M

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	154	-54	46	323	-51	127	-224	452	13	106
Net Cash From Operating Activities	-8.31	104	-541	-642	-615	-278	-563	-383	-308	-189
Net Cash From Continuing Operating Activities	-8.31	104	-541	-642	-615	-278	-563	-383	-308	-189
Net Income / (Loss) Continuing Operations	-278	-440	-1,131	-853	-858	-886	-761	-491	-410	-290
Consolidated Net Income / (Loss)	-278	-440	-1,131	-853	-858	-886	-761	-491	-410	-290
Depreciation Expense	57	54	44	48	35	17	15	12	15	19
Non-Cash Adjustments To Reconcile Net Income	402	345	445	227	170	164	170	95	72	47
Changes in Operating Assets and Liabilities, net	-189	145	101	-105	-1.44	390	14	1.48	15	35
Net Cash From Investing Activities	-117	-336	169	-273	-436	-418	273	-290	143	-321
Net Cash From Continuing Investing Activities	-117	-336	169	-273	-436	-418	273	-290	143	-321
Purchase of Property, Plant & Equipment	-34	-62	-72	-76	-70	-140	-127	-104	-65	-13
Purchase of Investments	-1,712	-1,882	-2,075	-1,698	-2,052	-2,076	-1,119	-903	-909	-1,035
Sale and/or Maturity of Investments	1,630	1,612	2,322	1,506	1,692	1,805	1,519	717	1,116	727
Other Investing Activities, net	-0.12	-4.44	-4.69	-4.20	-5.30	-7.00	0.00	0.00	-	-
Net Cash From Financing Activities	294	172	426	1,247	995	823	65	1,125	178	616
Net Cash From Continuing Financing Activities	294	172	426	1,247	995	823	65	1,125	178	616
Repayment of Debt	0.00	0.00	-762	500	0.00	-	0.00	-120	-	-
Issuance of Debt	0.00	0.00	1,016	0.00	200	0.00	0.00	-	150	-
Issuance of Common Equity	303	147	259	246	300	853	65	1,245	28	617
Other Financing Activities, net	-8.79	25	-88	501	495	-30	0.00	-	-0.60	0.38
Effect of Exchange Rate Changes	-15	6.39	-7.43	-9.02	4.92	-0.08	-	-	-	-
Cash Interest Paid	68	32	45	25	0.00	0.17	-	2.43	1.10	-
Cash Income Taxes Paid	14	6.02	2.65	-	-	-	-	0.11	0.11	0.07

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	54	-134	131	286	-130	-220	375	-14	-194	-207	498
Net Cash From Operating Activities	-118	-95	44	124	-82	-30	359	-59	-166	-132	-115
Net Cash From Continuing Operating Activities	-118	-95	44	124	-82	-30	359	-59	-166	-132	-115
Net Income / (Loss) Continuing Operations	-57	-84	-112	-17	-66	-138	148	-276	-174	-207	-406
Consolidated Net Income / (Loss)	-57	-84	-112	-17	-66	-138	148	-276	-174	-207	-406
Depreciation Expense	14	14	14	15	14	13	13	13	14	14	11
Non-Cash Adjustments To Reconcile Net Income	93	127	78	120	77	69	108	101	67	61	237
Changes in Operating Assets and Liabilities, net	-168	-117	50	-3.84	-118	58	80	93	-86	31	33
Net Cash From Investing Activities	114	-53	-30	34	-68	-241	-11	-8.71	-76	-140	314
Net Cash From Continuing Investing Activities	114	-53	-30	34	-68	-241	-11	-8.71	-76	-140	314
Purchase of Property, Plant & Equipment	-8.97	-9.09	-4.19	-8.02	-13	-15	-17	-16	-14	-22	-17
Purchase of Investments	-450	-487	-450	-316	-460	-589	-421	-386	-485	-723	-223
Sale and/or Maturity of Investments	573	443	424	358	405	364	432	394	423	605	558
Net Cash From Financing Activities	44	31	103	131	29	39	33	53	46	63	297
Net Cash From Continuing Financing Activities	44	31	103	131	29	39	33	53	46	63	297
Issuance of Common Equity	49	36	108	133	26	31	25	49	42	57	153
Other Financing Activities, net	-5.28	-5.28	-5.28	-1.28	3.05	8.33	8.33	4.00	4.00	7.50	-111
Effect of Exchange Rate Changes	14	-17	15	-3.12	-9.94	11	-6.55	-0.13	2.18	1.62	2.02
Cash Interest Paid	67	12	16	8.16	31	5.44	9.55	3.22	14	1.30	15
Cash Income Taxes Paid	2.97	-	-	-	-	-	-	-	-	-	-

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	4,240	3,830	3,546	3,643	3,407	2,395	1,575	1,995	1,263	1,387
Total Current Assets	3,295	2,983	2,692	2,809	2,615	1,716	1,201	1,765	672	1,105
Cash & Equivalents	966	813	866	820	497	547	420	645	194	181
Short-Term Investments	1,728	1,627	1,326	1,616	1,378	989	664	1,045	433	900
Accounts Receivable	405	328	238	199	102	43	19	34	23	8.30
Inventories, net	79	89	129	86	75	56	24	-	-	-
Prepaid Expenses	117	126	133	88	63	80	74	40	22	17
Plant, Property, & Equipment, net	503	526	523	502	465	425	321	182	115	28
Total Noncurrent Assets	442	321	331	333	327	254	53	48	476	253
Long-Term Investments	69	49	49	41	41	15	45	44	475	252
Noncurrent Deferred & Refundable Income Taxes	117	10	-	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	256	262	281	292	287	239	8.62	4.17	1.56	1.47
Total Liabilities & Shareholders' Equity	4,240	3,830	3,546	3,643	3,407	2,395	1,575	1,995	1,263	1,387
Total Liabilities	4,173	4,051	3,705	3,055	2,391	956	273	228	343	122
Total Current Liabilities	1,186	968	768	696	585	353	179	144	132	62
Accounts Payable	88	56	98	73	52	50	60	28	54	17
Accrued Expenses	887	713	545	395	356	197	113	72	42	29
Current Deferred Revenue	55	103	42	149	127	78	7.07	44	35	17
Other Current Liabilities	155	97	82	78	50	28	0.00	-	-	-
Total Noncurrent Liabilities	2,987	3,083	2,937	2,359	1,614	604	93	84	211	60
Long-Term Debt	1,025	1,021	1,017	676	-	0.00	30	30	150	-
Noncurrent Deferred Revenue	0.00	188	194	152	225	318	58	50	58	58
Other Noncurrent Operating Liabilities	1,962	1,874	1,726	1,531	1,389	285	4.97	4.35	3.07	1.30
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	67	-221	-158	588	1,016	1,439	1,302	1,766	920	1,265
Total Preferred & Common Equity	67	-221	-158	588	1,016	1,439	1,302	1,766	920	1,265
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	67	-221	-158	588	1,016	1,439	1,302	1,766	920	1,265
Common Stock	7,389	6,812	6,456	6,060	5,645	5,202	4,176	3,949	2,610	2,507
Retained Earnings	-7,288	-7,010	-6,569	-5,438	-4,585	-3,727	-2,841	-2,148	-1,657	-1,247
Accumulated Other Comprehensive Income / (Loss)	-35	-23	-45	-33	-44	-37	-33	-34	-33	4.37

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	4,214	4,205	4,010	3,824	3,839	3,402	3,392	3,535
Total Current Assets	3,268	3,355	3,173	2,989	2,985	2,524	2,541	2,691
Cash & Equivalents	1,020	1,100	968	682	1,033	658	672	1,073
Short-Term Investments	1,613	1,680	1,656	1,689	1,373	1,400	1,398	1,192
Accounts Receivable	418	354	309	321	325	221	219	185
Inventories, net	66	76	84	94	96	100	132	115
Prepaid Expenses	152	145	155	202	158	145	119	126
Plant, Property, & Equipment, net	499	507	517	523	526	527	523	515
Total Noncurrent Assets	447	343	320	312	328	351	328	330
Long-Term Investments	69	69	49	49	49	49	49	49
Noncurrent Deferred & Refundable Income Taxes	107	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	271	274	270	263	279	301	279	280
Total Liabilities & Shareholders' Equity	4,214	4,205	4,010	3,824	3,839	3,402	3,392	3,535
Total Liabilities	4,098	4,173	4,013	4,044	4,005	3,811	3,651	3,603
Total Current Liabilities	1,076	1,221	1,055	942	950	789	673	773
Accounts Payable	97	71	74	78	74	60	62	41
Accrued Expenses	704	946	809	699	713	599	509	511
Current Deferred Revenue	28	71	69	77	77	55	36	144
Other Current Liabilities	246	133	104	88	86	76	67	77
Total Noncurrent Liabilities	3,023	2,952	2,957	3,102	3,055	3,022	2,978	2,830
Long-Term Debt	1,026	1,024	1,023	1,022	1,020	1,019	1,018	1,016
Other Noncurrent Operating Liabilities	1,997	1,927	1,932	1,895	1,839	1,809	1,769	1,681
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	115	32	-3.07	-219	-166	-408	-259	-68
Total Preferred & Common Equity	115	32	-3.07	-219	-166	-408	-259	-68
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	115	32	-3.07	-219	-166	-408	-259	-68
Common Stock	7,498	7,261	7,124	6,883	6,738	6,648	6,523	6,338
Retained Earnings	-7,345	-7,204	-7,092	-7,076	-6,872	-7,019	-6,743	-6,362
Accumulated Other Comprehensive Income / (Loss)	-38	-25	-35	-27	-32	-37	-39	-44

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.97%	76.23%	22.88%	71.31%	124.28%	193.36%	-16.69%	90.66%	14.75%	-18.72%
EBITDA Growth	14.97%	59.56%	-40.86%	10.86%	19.40%	-11.57%	-57.71%	-21.80%	-45.65%	29.23%
EBIT Growth	12.34%	55.63%	-29.34%	7.83%	16.07%	-16.30%	-57.01%	-20.24%	-41.39%	26.60%
NOPAT Growth	37.31%	64.06%	-10.78%	14.46%	11.81%	-15.31%	-62.91%	-17.78%	-43.44%	26.91%
Net Income Growth	36.82%	61.08%	-32.64%	0.64%	3.14%	-16.37%	-55.13%	-19.69%	-41.38%	19.51%
EPS Growth	38.07%	62.15%	-29.17%	3.49%	8.01%	-7.13%	-39.67%	-13.15%	-38.84%	28.87%
Operating Cash Flow Growth	-107.98%	119.24%	15.65%	-4.35%	-120.87%	50.51%	-46.98%	-24.40%	-62.68%	-14.19%
Free Cash Flow Firm Growth	-230.57%	128.50%	-4,357.02%	-42.16%	104.50%	51.88%	-60.46%	-32.94%	-85.48%	51.25%
Invested Capital Growth	1.02%	-22.09%	-14.06%	-71.36%	-530.12%	-155.32%	227.96%	297.26%	53.62%	-68.11%
Revenue Q/Q Growth	7.33%	6.07%	7.96%	12.67%	22.91%	29.95%	-18.40%	29.48%	26.58%	-28.61%
EBITDA Q/Q Growth	-45.28%	2.89%	-0.48%	-3.27%	10.94%	-7.04%	-9.62%	-6.99%	-4.89%	-19.40%
EBIT Q/Q Growth	-15.98%	11.77%	3.51%	-2.93%	9.34%	-7.26%	-10.52%	-6.64%	-4.17%	-18.75%
NOPAT Q/Q Growth	5.98%	20.38%	0.75%	-0.05%	11.14%	-9.02%	-9.85%	-6.81%	-5.71%	-18.78%
Net Income Q/Q Growth	16.28%	13.66%	4.31%	-1.78%	3.66%	-7.88%	-10.00%	-6.35%	-5.73%	-31.41%
EPS Q/Q Growth	15.50%	15.18%	4.81%	-0.84%	4.36%	-4.38%	-8.76%	-3.24%	-5.51%	-45.57%
Operating Cash Flow Q/Q Growth	-114.70%	5,179.07%	3.25%	-4.39%	10.59%	-19.55%	-9.20%	-6.90%	-8.95%	-9.51%
Free Cash Flow Firm Q/Q Growth	-337.48%	949.02%	-3.45%	-77.55%	111.17%	-38.06%	-3.61%	-4.44%	-12.41%	-3.81%
Invested Capital Q/Q Growth	6.77%	-5.43%	-1.22%	-2.84%	-9.95%	12.81%	-10.37%	4.91%	16.85%	-27.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	85.62%	83.02%	83.73%	83.40%	84.16%	88.60%	97.59%	100.00%	100.00%	100.00%
EBITDA Margin	-13.38%	-19.35%	-84.32%	-73.55%	-141.35%	-393.33%	-1,034.19%	-546.33%	-855.16%	-673.73%
Operating Margin	-7.87%	-15.43%	-75.68%	-83.94%	-168.09%	-427.50%	-1,087.56%	-556.20%	-900.33%	-720.27%
EBIT Margin	-15.90%	-22.31%	-88.61%	-84.18%	-156.46%	-418.07%	-1,054.54%	-559.56%	-887.25%	-720.08%
Profit (Net Income) Margin	-12.37%	-24.08%	-109.04%	-101.01%	-174.15%	-403.24%	-1,016.58%	-545.95%	-869.63%	-705.83%
Tax Burden Percent	73.71%	101.55%	100.37%	100.08%	100.31%	100.10%	100.11%	100.00%	100.00%	100.00%
Interest Burden Percent	105.56%	106.29%	122.60%	119.90%	110.96%	96.36%	96.30%	97.57%	98.01%	98.02%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,450.22%	-430.59%	-2,294.21%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,432.97%	-416.95%	-2,283.60%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	1,385.55%	380.96%	2,257.67%	0.00%	0.00%
Return on Equity (ROE)	362.29%	232.40%	-526.14%	-106.31%	-69.92%	-64.66%	-49.63%	-36.54%	-37.54%	-26.36%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-537.12%	-716.28%	0.00%	0.00%
Operating Return on Assets (OROA)	-8.86%	-11.06%	-25.57%	-20.16%	-26.58%	-46.28%	-44.26%	-30.89%	-31.59%	-24.00%
Return on Assets (ROA)	-6.89%	-11.94%	-31.47%	-24.19%	-29.58%	-44.64%	-42.67%	-30.14%	-30.96%	-23.52%
Return on Common Equity (ROCE)	362.29%	232.40%	-526.14%	-106.31%	-69.92%	-64.66%	-49.63%	-36.54%	-37.54%	-26.36%
Return on Equity Simple (ROE_SIMPLE)	-414.62%	199.53%	714.91%	-144.99%	-84.46%	-61.59%	-58.49%	-27.79%	-44.57%	-22.94%
Net Operating Profit after Tax (NOPAT)	-124	-198	-550	-496	-580	-658	-570	-350	-297	-207
NOPAT Margin	-5.51%	-10.80%	-52.97%	-58.75%	-117.66%	-299.25%	-761.30%	-389.34%	-630.23%	-504.19%
Net Nonoperating Expense Percent (NNEP)	-9.63%	-18.03%	-38.45%	-20.24%	-17.00%	-17.25%	-13.64%	-10.60%	-9.89%	-7.18%
Return On Investment Capital (ROIC_SIMPLE)	-11.34%	-24.69%	-64.00%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	14.38%	16.98%	16.27%	16.60%	15.84%	11.40%	2.41%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	43.39%	43.52%	74.29%	73.51%	119.39%	217.98%	510.44%	221.73%	189.47%	147.48%
R&D to Revenue	50.09%	54.94%	85.12%	93.83%	132.86%	298.12%	674.72%	434.46%	810.86%	672.79%
Operating Expenses to Revenue	93.48%	98.46%	159.40%	167.34%	252.25%	516.10%	1,185.16%	656.20%	1,000.33%	820.27%
Earnings before Interest and Taxes (EBIT)	-358	-408	-919	-711	-771	-919	-790	-503	-418	-296
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-301	-354	-875	-621	-697	-864	-775	-491	-403	-277
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	452.40	0.00	0.00	34.48	14.86	8.93	5.66	6.67	3.49	6.31
Price to Tangible Book Value (P/TBV)	452.40	0.00	0.00	34.48	14.86	8.93	5.66	6.67	3.49	6.31
Price to Revenue (P/Rev)	13.50	13.14	28.18	24.02	30.64	58.43	98.34	131.03	68.13	194.10
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	30.87	162.81	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	12.73	12.34	27.00	21.89	26.75	51.37	83.66	112.08	47.95	161.68
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	216.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	208.74	0.00	2,075.70	856.53	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	15.27	-4.63	-6.43	1.15	0.00	0.00	0.02	0.02	0.16	0.00
Long-Term Debt to Equity	15.27	-4.63	-6.43	1.15	0.00	0.00	0.02	0.02	0.16	0.00
Financial Leverage	20.88	7.11	-7.04	-2.20	-1.33	-0.97	-0.91	-0.99	-1.05	-1.05
Leverage Ratio	-52.55	-19.47	16.72	4.39	2.36	1.45	1.16	1.21	1.21	1.12
Compound Leverage Factor	-55.47	-20.69	20.50	5.27	2.62	1.40	1.12	1.18	1.19	1.10
Debt to Total Capital	93.85%	127.58%	118.43%	53.46%	0.00%	0.00%	2.25%	1.67%	14.02%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	93.85%	127.58%	118.43%	53.46%	0.00%	0.00%	2.25%	1.67%	14.02%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	6.15%	-27.58%	-18.43%	46.54%	100.00%	100.00%	97.75%	98.33%	85.98%	100.00%
Debt to EBITDA	-3.41	-2.89	-1.16	-1.09	0.00	0.00	-0.04	-0.06	-0.37	0.00
Net Debt to EBITDA	5.78	4.15	1.40	2.90	0.00	0.00	1.42	3.47	2.36	0.00
Long-Term Debt to EBITDA	-3.41	-2.89	-1.16	-1.09	0.00	0.00	-0.04	-0.06	-0.37	0.00
Debt to NOPAT	-8.28	-5.17	-1.85	-1.36	0.00	0.00	-0.05	-0.09	-0.50	0.00
Net Debt to NOPAT	14.04	7.43	2.23	3.63	0.00	0.00	1.93	4.87	3.20	0.00
Long-Term Debt to NOPAT	-8.28	-5.17	-1.85	-1.36	0.00	0.00	-0.05	-0.09	-0.50	0.00
Altman Z-Score	2.81	1.75	2.23	2.18	2.02	5.39	12.84	29.64	3.25	38.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.78	3.08	3.51	4.04	4.47	4.87	6.69	12.23	5.10	17.80
Quick Ratio	2.61	2.86	3.16	3.79	3.38	4.48	6.14	11.96	4.94	17.53
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-141	108	-379	8.90	15	-342	-711	-443	-333	-180
Operating Cash Flow to CapEx	-24.25%	167.42%	-751.15%	-840.22%	-874.01%	-198.66%	-443.40%	-367.33%	-476.63%	-1,460.54%
Free Cash Flow to Firm to Interest Expense	-0.99	0.89	-1.63	0.06	0.18	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-0.06	0.86	-2.33	-4.49	-7.28	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-0.30	0.35	-2.64	-5.02	-8.11	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.50	0.29	0.24	0.17	0.11	0.04	0.06	0.04	0.03
Accounts Receivable Turnover	6.13	6.46	4.75	5.61	6.78	7.12	2.84	3.14	2.98	1.70
Inventory Turnover	3.86	2.85	1.57	1.73	1.19	0.62	0.00	0.00	0.00	0.00
Fixed Asset Turnover	4.37	3.48	2.02	1.75	1.11	0.59	0.30	0.61	0.66	1.66
Accounts Payable Turnover	4.49	4.04	1.97	2.24	1.53	0.46	0.04	0.00	0.00	0.00
Days Sales Outstanding (DSO)	59.51	56.47	76.79	65.06	53.85	51.30	128.55	116.38	122.41	214.20
Days Inventory Outstanding (DIO)	94.62	128.23	232.78	210.40	307.59	585.58	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	81.23	90.32	185.42	163.29	238.14	798.04	8,918.70	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	72.90	94.39	124.15	112.17	123.29	-161.16	-8,790.15	116.38	122.41	214.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,671	-1,689	-1,383	-1,213	-708	-112	203	62	-31	-68
Invested Capital Turnover	-1.34	-1.19	-0.80	-0.88	-1.20	4.85	0.57	5.89	-0.95	-0.76
Increase / (Decrease) in Invested Capital	17	-306	-171	-505	-595	-315	141	93	36	-27
Enterprise Value (EV)	28,612	22,553	28,013	18,481	13,185	11,289	6,267	10,077	2,261	6,645
Market Capitalization	30,350	24,021	29,238	20,282	15,100	12,840	7,366	11,781	3,213	7,977
Book Value per Share	$0.52	($1.76)	($1.29)	$4.92	$8.75	$12.90	$12.89	$19.05	$10.72	$14.93
Tangible Book Value per Share	$0.52	($1.76)	($1.29)	$4.92	$8.75	$12.90	$12.89	$19.05	$10.72	$14.93
Total Capital	1,092	800	859	1,264	1,016	1,439	1,332	1,796	1,070	1,265
Total Debt	1,025	1,021	1,017	676	0.00	0.00	30	30	150	0.00
Total Long-Term Debt	1,025	1,021	1,017	676	0.00	0.00	30	30	150	0.00
Net Debt	-1,738	-1,468	-1,225	-1,801	-1,915	-1,551	-1,099	-1,705	-952	-1,332
Capital Expenditures (CapEx)	34	62	72	76	70	140	127	104	65	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-585	-424	-268	-323	155	-173	-63	-70	-87	-37
Debt-free Net Working Capital (DFNWC)	2,109	2,015	1,924	2,113	2,030	1,363	1,021	1,620	540	1,043
Net Working Capital (NWC)	2,109	2,015	1,924	2,113	2,030	1,363	1,021	1,620	540	1,043
Net Nonoperating Expense (NNE)	154	243	582	357	278	229	191	141	113	83
Net Nonoperating Obligations (NNO)	-1,738	-1,468	-1,225	-1,801	-1,724	-1,551	-1,099	-1,705	-952	-1,332
Total Depreciation and Amortization (D&A)	57	54	44	90	74	54	15	12	15	19
Debt-free, Cash-free Net Working Capital to Revenue	-26.04%	-23.22%	-25.84%	-38.22%	31.47%	-78.68%	-84.04%	-78.00%	-183.68%	-90.62%
Debt-free Net Working Capital to Revenue	93.81%	110.21%	185.49%	250.25%	411.79%	620.37%	1,363.28%	1,802.31%	1,145.44%	2,538.60%
Net Working Capital to Revenue	93.81%	110.21%	185.49%	250.25%	411.79%	620.37%	1,363.28%	1,802.31%	1,145.44%	2,538.60%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.18)	($3.52)	($9.30)	($7.20)	($7.46)	($8.11)	($7.57)	($5.42)	($4.79)	($3.45)
Adjusted Weighted Average Basic Shares Outstanding	127.65M	124.91M	121.69M	118.45M	117.00M	112.58M	106.26M	99.87M	86.01M	85.14M
Adjusted Diluted Earnings per Share	($2.18)	($3.52)	($9.30)	($7.20)	($7.46)	($8.11)	($7.57)	($5.42)	($4.79)	($3.45)
Adjusted Weighted Average Diluted Shares Outstanding	127.65M	124.91M	121.69M	118.45M	117.00M	112.58M	106.26M	99.87M	86.01M	85.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($7.46)	($8.11)	($7.57)	($5.42)	($4.79)	($3.45)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	129.46M	125.95M	124.13M	120.21M	114.99M	109.26M	100.59M	90.55M	85.60M	83.99M
Normalized Net Operating Profit after Tax (NOPAT)	-124	-198	-550	-496	-580	-658	-570	-350	-297	-207
Normalized NOPAT Margin	-5.51%	-10.80%	-52.97%	-58.75%	-117.66%	-299.25%	-761.30%	-389.34%	-630.23%	-504.19%
Pre Tax Income Margin	-16.79%	-23.71%	-108.63%	-100.93%	-173.60%	-402.85%	-1,015.48%	-545.95%	-869.63%	-705.83%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.52	-3.36	-3.95	-4.97	-9.13	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-0.87	-1.63	-2.36	-3.47	-6.86	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-2.76	-3.88	-4.26	-5.50	-9.96	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-1.11	-2.14	-2.67	-4.00	-7.70	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	20.20%	34.90%	-33.26%	107.00%	54.82%	31.25%	183.96%	41.78%	49.72%	29.59%	40.86%
EBITDA Growth	61.27%	-39.40%	-144.17%	107.28%	76.11%	30.30%	165.26%	-13.14%	23.70%	12.94%	-95.71%
EBIT Growth	45.46%	-36.01%	-168.14%	97.33%	64.22%	28.47%	152.76%	-13.37%	18.15%	14.88%	-80.59%
NOPAT Growth	141.62%	9.66%	-125.68%	121.15%	71.01%	38.28%	216.05%	-19.90%	-2.10%	3.06%	-42.03%
Net Income Growth	12.82%	39.24%	-175.51%	93.88%	62.13%	33.55%	136.40%	0.50%	27.56%	19.72%	-98.48%
EPS Growth	15.38%	37.74%	-175.65%	94.12%	62.86%	37.28%	134.64%	3.49%	30.00%	21.76%	-93.02%
Operating Cash Flow Growth	-45.14%	-217.71%	-87.84%	310.49%	51.03%	77.42%	411.76%	51.97%	2.76%	12.10%	13.99%
Free Cash Flow Firm Growth	-120.21%	-140.55%	-69.15%	561.59%	319.44%	482.15%	6,551.30%	-94.39%	-88.45%	-89.56%	-98.36%
Invested Capital Growth	3.61%	1.02%	-11.93%	-10.58%	-18.86%	-22.09%	-17.22%	-14.54%	-13.21%	-14.06%	-15.89%
Revenue Q/Q Growth	0.17%	18.42%	-24.08%	33.48%	12.42%	-41.41%	135.46%	-0.17%	-4.70%	26.76%	17.56%
EBITDA Q/Q Growth	89.98%	-116.43%	-551.08%	154.17%	71.19%	-168.58%	174.33%	-77.82%	18.23%	35.79%	-28.88%
EBIT Q/Q Growth	83.00%	-74.76%	-1,400.96%	87.77%	57.60%	-187.55%	158.89%	-63.67%	15.23%	35.43%	-26.56%
NOPAT Q/Q Growth	117.19%	-36.74%	-258.20%	211.92%	62.69%	-138.87%	230.30%	-53.42%	20.57%	26.91%	-34.62%
Net Income Q/Q Growth	31.38%	24.92%	-560.61%	74.39%	52.18%	-193.31%	153.53%	-58.54%	16.09%	48.88%	-46.33%
EPS Q/Q Growth	33.33%	24.14%	-569.23%	75.00%	50.94%	-192.17%	152.04%	-57.86%	17.16%	49.10%	-44.98%
Operating Cash Flow Q/Q Growth	-24.99%	-316.58%	-64.80%	252.31%	-173.59%	-108.29%	709.32%	64.57%	-26.14%	-14.48%	6.14%
Free Cash Flow Firm Q/Q Growth	49.66%	-166.20%	-28.61%	-15.07%	1.03%	-49.64%	1,431.15%	-46.16%	40.22%	475.37%	-98.71%
Invested Capital Q/Q Growth	6.68%	6.77%	-8.37%	-2.24%	4.17%	-5.43%	-7.05%	-9.90%	1.57%	-1.22%	-4.60%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.04%	82.67%	82.85%	89.59%	86.65%	80.47%	88.77%	73.22%	82.82%	84.70%	84.44%
EBITDA Margin	-2.90%	-28.97%	-15.85%	2.67%	-6.57%	-28.03%	23.95%	-75.86%	-42.59%	-52.79%	-104.21%
Operating Margin	3.04%	-17.73%	-15.35%	7.37%	-8.79%	-26.47%	28.50%	-72.10%	-46.92%	-56.30%	-97.63%
EBIT Margin	-5.32%	-31.36%	-21.25%	-1.07%	-11.73%	-31.10%	20.81%	-83.21%	-50.76%	-57.06%	-112.03%
Profit (Net Income) Margin	-9.67%	-14.12%	-22.27%	-2.56%	-13.34%	-31.35%	19.69%	-86.59%	-54.53%	-61.93%	-153.58%
Tax Burden Percent	138.18%	43.19%	102.68%	151.24%	103.69%	100.13%	98.02%	100.66%	101.01%	100.23%	99.99%
Interest Burden Percent	131.54%	104.28%	102.10%	157.48%	109.67%	100.68%	96.50%	103.38%	106.36%	108.28%	137.10%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.98%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	519.47%	362.29%	497.73%	35.48%	138.80%	232.40%	436.71%	916.48%	-1,500.66%	-526.14%	-343.51%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-3.11%	-17.47%	-11.07%	-0.68%	-6.51%	-15.42%	9.73%	-30.59%	-17.01%	-16.47%	-30.72%
Return on Assets (ROA)	-5.65%	-7.87%	-11.60%	-1.62%	-7.41%	-15.54%	9.20%	-31.83%	-18.27%	-17.87%	-42.12%
Return on Common Equity (ROCE)	519.47%	362.29%	497.73%	35.48%	138.80%	232.40%	436.71%	916.48%	-1,500.66%	-526.14%	-343.51%
Return on Equity Simple (ROE_SIMPLE)	-233.64%	0.00%	-1,026.96%	2,378.25%	151.44%	0.00%	307.40%	260.59%	410.78%	0.00%	1,747.72%
Net Operating Profit after Tax (NOPAT)	13	-74	-54	34	-30	-81	210	-161	-105	-132	-181
NOPAT Margin	2.13%	-12.41%	-10.75%	5.16%	-6.15%	-18.53%	27.93%	-50.47%	-32.84%	-39.41%	-68.34%
Net Nonoperating Expense Percent (NNEP)	-4.56%	-0.63%	-3.54%	-3.72%	-2.84%	-4.19%	-4.53%	-8.96%	-5.12%	-4.99%	-13.93%
Return On Investment Capital (ROIC_SIMPLE)	1.11%	-6.74%	-	-	-	-10.18%	-	-	-	-15.38%	-
Cost of Revenue to Revenue	11.96%	17.33%	17.15%	10.41%	13.35%	19.53%	11.23%	26.78%	17.18%	15.30%	15.56%
SG&A Expenses to Revenue	40.38%	49.79%	44.12%	37.65%	42.64%	45.06%	26.54%	67.35%	57.52%	62.78%	89.24%
R&D to Revenue	44.62%	50.60%	54.09%	44.58%	52.80%	61.89%	33.73%	77.97%	72.21%	78.21%	92.84%
Operating Expenses to Revenue	85.00%	100.39%	98.20%	82.22%	95.44%	106.95%	60.27%	145.32%	129.73%	141.00%	182.07%
Earnings before Interest and Taxes (EBIT)	-32	-186	-106	-7.09	-58	-137	156	-265	-162	-191	-296
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-172	-79	18	-32	-123	180	-242	-136	-177	-275
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	302.82	452.40	1,091.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	302.82	452.40	1,091.32	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	14.89	13.50	16.86	13.11	9.36	13.14	12.84	19.11	21.75	28.18	25.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	14.17	12.73	15.98	12.41	8.66	12.34	12.01	18.24	20.78	27.00	23.65
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	558.63	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	404.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	592.05	78.13	91.77	216.53	10,492.53	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	563.66	126.41	129.78	208.74	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	8.88	15.27	31.64	-333.45	-4.66	-4.63	-6.15	-2.50	-3.93	-6.43	-15.02
Long-Term Debt to Equity	8.88	15.27	31.64	-333.45	-4.66	-4.63	-6.15	-2.50	-3.93	-6.43	-15.02
Financial Leverage	29.61	20.88	24.43	6.66	5.23	7.11	11.71	11.07	-19.07	-7.04	-4.70
Leverage Ratio	-77.41	-52.55	-60.25	-18.03	-15.08	-19.47	-31.58	-29.01	48.09	16.72	10.18
Compound Leverage Factor	-101.83	-54.80	-61.51	-28.39	-16.54	-19.60	-30.48	-29.99	51.15	18.11	13.96
Debt to Total Capital	89.88%	93.85%	96.94%	100.30%	127.33%	127.58%	119.42%	166.83%	134.17%	118.43%	107.13%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	89.88%	93.85%	96.94%	100.30%	127.33%	127.58%	119.42%	166.83%	134.17%	118.43%	107.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	10.12%	6.15%	3.06%	-0.30%	-27.33%	-27.58%	-19.42%	-66.83%	-34.17%	-18.43%	-7.13%
Debt to EBITDA	-3.75	-3.41	-4.94	19.64	-4.93	-2.89	-2.80	-1.24	-1.29	-1.16	-1.17
Net Debt to EBITDA	6.12	5.78	8.81	-31.72	6.75	4.15	3.94	1.33	1.39	1.40	1.49
Long-Term Debt to EBITDA	-3.75	-3.41	-4.94	19.64	-4.93	-2.89	-2.80	-1.24	-1.29	-1.16	-1.17
Debt to NOPAT	-12.70	-8.28	-7.77	14.23	-8.30	-5.17	-4.11	-1.76	-1.85	-1.85	-1.83
Net Debt to NOPAT	20.74	14.04	13.86	-22.98	11.37	7.43	5.79	1.88	2.00	2.23	2.35
Long-Term Debt to NOPAT	-12.70	-8.28	-7.77	14.23	-8.30	-5.17	-4.11	-1.76	-1.85	-1.85	-1.83
Altman Z-Score	3.83	2.94	3.70	3.33	1.31	1.99	2.03	1.55	2.14	2.91	2.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.04	2.78	2.75	3.01	3.17	3.08	3.14	3.20	3.77	3.51	3.48
Quick Ratio	2.84	2.61	2.57	2.78	2.86	2.86	2.88	2.89	3.40	3.16	3.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-46	-91	137	192	226	224	445	29	54	38	6.69
Operating Cash Flow to CapEx	-1,319.00%	-1,040.93%	1,042.63%	1,548.49%	-628.34%	-194.62%	2,102.81%	-370.54%	-1,198.44%	-610.02%	-698.27%
Free Cash Flow to Firm to Interest Expense	-1.18	-2.33	3.99	5.78	6.42	7.15	14.40	0.97	1.86	1.29	0.06
Operating Cash Flow to Interest Expense	-3.06	-2.43	1.27	3.73	-2.31	-0.95	11.63	-1.96	-5.75	-4.41	-0.98
Operating Cash Flow Less CapEx to Interest Expense	-3.29	-2.66	1.15	3.49	-2.68	-1.44	11.08	-2.49	-6.23	-5.14	-1.12
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.56	0.52	0.63	0.56	0.50	0.47	0.37	0.34	0.29	0.27
Accounts Receivable Turnover	6.35	6.13	6.17	8.84	7.41	6.46	6.76	6.82	6.08	4.75	5.90
Inventory Turnover	4.12	3.86	3.57	3.31	2.85	2.85	2.61	2.46	1.79	1.57	1.45
Fixed Asset Turnover	4.59	4.37	4.06	4.49	3.83	3.48	3.31	2.39	2.23	2.02	1.92
Accounts Payable Turnover	3.74	4.49	4.24	4.56	4.58	4.04	4.82	4.15	3.21	1.97	3.85
Days Sales Outstanding (DSO)	57.47	59.51	59.18	41.27	49.27	56.47	54.00	53.52	60.01	76.79	61.83
Days Inventory Outstanding (DIO)	88.67	94.62	102.30	110.43	128.21	128.23	139.79	148.61	204.18	232.78	250.90
Days Payable Outstanding (DPO)	97.55	81.23	86.15	80.06	79.69	90.32	75.70	88.00	113.69	185.42	94.79
Cash Conversion Cycle (CCC)	48.59	72.90	75.33	71.63	97.79	94.39	118.08	114.14	150.49	124.15	217.94
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-1,560	-1,671	-1,793	-1,654	-1,618	-1,689	-1,602	-1,496	-1,361	-1,383	-1,366
Invested Capital Turnover	-1.48	-1.34	-1.23	-1.49	-1.34	-1.19	-1.16	-0.88	-0.89	-0.80	-0.76
Increase / (Decrease) in Invested Capital	58	17	-191	-158	-257	-306	-235	-190	-159	-171	-187
Enterprise Value (EV)	33,281	28,612	33,483	29,086	17,356	22,553	20,702	22,564	23,764	28,013	22,726
Market Capitalization	34,956	30,350	35,308	30,738	18,755	24,021	22,138	23,652	24,866	29,238	24,025
Book Value per Share	$0.89	$0.52	$0.25	($0.02)	($1.74)	($1.76)	($1.33)	($3.28)	($2.09)	($1.29)	($0.56)
Tangible Book Value per Share	$0.89	$0.52	$0.25	($0.02)	($1.74)	($1.76)	($1.33)	($3.28)	($2.09)	($1.29)	($0.56)
Total Capital	1,141	1,092	1,056	1,020	802	800	854	611	759	859	948
Total Debt	1,026	1,025	1,024	1,023	1,022	1,021	1,020	1,019	1,018	1,017	1,016
Total Long-Term Debt	1,026	1,025	1,024	1,023	1,022	1,021	1,020	1,019	1,018	1,017	1,016
Net Debt	-1,675	-1,738	-1,825	-1,651	-1,399	-1,468	-1,436	-1,088	-1,102	-1,225	-1,299
Capital Expenditures (CapEx)	8.97	9.09	4.19	8.02	13	15	17	16	14	22	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-440	-585	-645	-507	-324	-424	-371	-322	-203	-268	-347
Debt-free Net Working Capital (DFNWC)	2,193	2,109	2,135	2,118	2,047	2,015	2,036	1,735	1,868	1,924	1,918
Net Working Capital (NWC)	2,193	2,109	2,135	2,118	2,047	2,015	2,036	1,735	1,868	1,924	1,918
Net Nonoperating Expense (NNE)	70	10	58	51	36	56	62	115	69	75	225
Net Nonoperating Obligations (NNO)	-1,675	-1,738	-1,825	-1,651	-1,399	-1,468	-1,436	-1,088	-1,102	-1,225	-1,299
Total Depreciation and Amortization (D&A)	14	14	27	25	25	13	24	23	26	14	21
Debt-free, Cash-free Net Working Capital to Revenue	-18.72%	-26.04%	-30.81%	-21.63%	-16.19%	-23.22%	-21.50%	-26.03%	-17.76%	-25.84%	-36.14%
Debt-free Net Working Capital to Revenue	93.38%	93.81%	101.91%	90.33%	102.17%	110.21%	118.10%	140.25%	163.33%	185.49%	199.61%
Net Working Capital to Revenue	93.38%	93.81%	101.91%	90.33%	102.17%	110.21%	118.10%	140.25%	163.33%	185.49%	199.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.44)	($0.66)	($0.87)	($0.13)	($0.52)	($1.09)	$1.18	($2.21)	($1.40)	($1.69)	($3.32)
Adjusted Weighted Average Basic Shares Outstanding	129.68M	127.65M	128.59M	126.73M	126.14M	124.91M	125.22M	124.66M	124.11M	121.69M	122.17M
Adjusted Diluted Earnings per Share	($0.44)	($0.66)	($0.87)	($0.13)	($0.52)	($1.06)	$1.15	($2.21)	($1.40)	($1.69)	($3.32)
Adjusted Weighted Average Diluted Shares Outstanding	129.68M	127.65M	128.59M	126.73M	126.14M	124.91M	131.34M	124.66M	124.11M	121.69M	122.17M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	130.39M	129.46M	128.98M	128.38M	126.49M	125.95M	125.49M	125.00M	124.53M	124.13M	123.03M
Normalized Net Operating Profit after Tax (NOPAT)	13	-74	-54	34	-30	-81	210	-161	-105	-132	-181
Normalized NOPAT Margin	2.13%	-12.41%	-10.75%	5.16%	-6.15%	-18.53%	27.93%	-50.47%	-32.84%	-39.41%	-68.34%
Pre Tax Income Margin	-7.00%	-32.70%	-21.69%	-1.69%	-12.86%	-31.31%	20.08%	-86.03%	-53.98%	-61.79%	-153.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.82	-4.77	-3.10	-0.21	-1.64	-4.36	5.06	-8.83	-5.60	-6.39	-2.52
NOPAT to Interest Expense	0.33	-1.89	-1.57	1.02	-0.86	-2.60	6.79	-5.36	-3.62	-4.41	-1.54
EBIT Less CapEx to Interest Expense	-1.05	-5.01	-3.22	-0.45	-2.01	-4.85	4.50	-9.36	-6.08	-7.11	-2.66
NOPAT Less CapEx to Interest Expense	0.10	-2.12	-1.69	0.78	-1.23	-3.09	6.23	-5.89	-4.10	-5.14	-1.68
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

When does Alnylam Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Alnylam Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Alnylam Pharmaceuticals' net income changed over the last 9 years?

Alnylam Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$278.16 million in 2024, falling from -$290.07 million in 2015. The previous period was -$440.24 million in 2023. See where experts think Alnylam Pharmaceuticals is headed by visiting Alnylam Pharmaceuticals' forecast page.

What is Alnylam Pharmaceuticals's operating income?

Alnylam Pharmaceuticals's total operating income in 2024 was -$176.89 million, based on the following breakdown:

Total Gross Profit: $1.92 billion
Total Operating Expenses: $2.10 billion

How has Alnylam Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' total revenue changed from $41.10 million in 2015 to $2.25 billion in 2024, a change of 5,370.6%.

How much debt does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals' total liabilities were at $4.17 billion at the end of 2024, a 3.0% increase from 2023, and a 3,326.1% increase since 2015.

How much cash does Alnylam Pharmaceuticals have?

In the past 9 years, Alnylam Pharmaceuticals' cash and equivalents has ranged from $180.90 million in 2015 to $966.43 million in 2024, and is currently $966.43 million as of their latest financial filing in 2024.

How has Alnylam Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' book value per share changed from 14.93 in 2015 to 0.52 in 2024, a change of -96.5%.

Related Companies

This page (NASDAQ:ALNY) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Financials

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alnylam Pharmaceuticals (ALNY) Financials

Annual Income Statements for Alnylam Pharmaceuticals

Quarterly Income Statements for Alnylam Pharmaceuticals

Annual Cash Flow Statements for Alnylam Pharmaceuticals

Quarterly Cash Flow Statements for Alnylam Pharmaceuticals

Annual Balance Sheets for Alnylam Pharmaceuticals

Quarterly Balance Sheets for Alnylam Pharmaceuticals

Annual Metrics And Ratios for Alnylam Pharmaceuticals

Quarterly Metrics And Ratios for Alnylam Pharmaceuticals

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools